Measures activity, not value. Not investment advice.
News volume hit 10.5 times its usual week, 58 articles, but the stock is down 1.7% in a year.
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 31 Dec 2025
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+8.6%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$10.2B
$7.0B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$6.54
$4.50
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
81.9%
81.1%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
23.4%
18.5%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
17.4%
13.0%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
22.9%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$11.8B
$9.9B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$5.7B
$5.5B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
26.4
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
4.6
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
5.6
Latest = 12 months to 31 Dec 2025; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$3K
bought $3K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-2.9%
1,433 13F filers vs 1,476
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
–
No 13F holdings or share count.
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
–
3.0M shares sold short (30 Oct 2026); no share count in the company's filings in our data
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.0
3.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-7.6%
3.3M shares sold short in the report before, 3.0M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
35%
35% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
840
Tracked since 21 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 21 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$5.9M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
66
66 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
11×
66 articles in the last 7 days; its usual week has 6.
Price $174.35 on 20 Nov 2026, -1.7% over 12 months (12-month range $155.62 to $209.48)
Sharp change
Lobbying filing
Insider net buying (open market). Insiders sold a net $2.2M in the last 12 months (the 12 months before: $0).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 24 published in the last 12 months (none in the 12 months before).Institutional holders (13F filers). 1,433 13F filers reported holding it in the latest 13F quarter, +16% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months.Lobbying spend. Lobbying spend: $5.9M published in the last 12 months, +3.5% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: revenue per quarter, capital spending per quarter, workers in warn layoff notices.
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $3K (11 Sep 2026), too little history to compare.
Wikipedia attention spike: drew 6,503 Wikipedia page views in the week of 3 Aug 2026, 1.2× the same week last year Public on 11 Aug 2026.
No new award in 12 months; the latest was signed 13 Aug 2021. New awards only; later changes to an award are not listed.
Signed
Agency
Amount
What for
Source
13 Aug 2021
Department of Health and Human ServicesNational Institutes of Health
$5.3M
A NOVEL AND HIGHLY SELECTIVE OREXIN 1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF PATIENTS WITH OPIOID USE DISORDER. - PROJECT SUMMARY OPIOID USE DISORDER (OUD) IS A PUBLIC HEALTH CRISIS. CURRENT TREATMENTS SHOW LIMITED EFFICACY AND FAIL TO PREVENT RELAPSE TO DRUG USE DURING ATTEMPTED ABSTINENCE AND DRUG-OVERDOSE ARE ALL TOO FREQUENT. IN COLLABORATION WITH EOLAS THERAPEUTICS AND THE NIH BLUEPRINT NEUROTHERAPEUTICS NETWORK, ASTRAZENECA HAS DEVELOPED A POTENT AND SELECTIVE OX1 RECEPTOR ANTAGONIST (AZGrant
A PHASE 1/2A CLINICAL TRIAL STUDY TO EVALUATE THE EFFICACY OF MEDI8852 IN THE TREATMENT OF INFLUENZA IN ADULTS CHALLENGED WITH A WILD-TYPE INFLUENZAGrant
840 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 18%, Marketing & communications 10%, Research & science 7%, Legal, policy & compliance 6%.
Reported lobbying spend: $970K in Q3 2026, $1.7M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
3 Aug 2026
New
Tholos Government Relationsfor Astrazeneca Pharmaceuticals LP
Issues related to pharmaceuticals, intellectual property, and tradePharmacy, Copyright/patents, Trade
Drug Pricing. General issues related to rare disease and orphan drugs. General issues related to diagnostics for patients with rare diseases. Items related to the Administrations Cancer Moonshot. Prescription Drug User Fee Act (PDUFA).; General issues related to patient access to rare disease therapies, Part B and Part D drugs. Issues related to home infusion for Part B patients. Issues related to home infusion for Part B patients.; Issues related to the 340B drug discount program.Pharmacy, Health issues, Medicare/Medicaid
Provide legislative and regulatory advice related to vaccine development, drug pricing, the 340B Drug Pricing Program, PDUFA Reauthorization, and clinical trial diversity; H.R.6000, Cures 2.0 Act; H.R.5585, Advanced Research Project Agency-Health Act; H.R.5030/S.2706, DIVERSE Trials Act; H.R.7667, FPharmacy
Educating and advocating on issues related to AstraZenecas efforts to substitute a non-global warming gas as the propellant in its metered dose inhalers.Environment
Two or more unrelated kinds of records unusual within 30 days
23 Mar 2021confirmed
Confirmed across sources Attention and Short interest and volume
AstraZeneca(AZN): drew 222K Wikipedia page views in the week of 15 Mar 2021, 38× the same week last year, while it had 135.1M shares sold short in the 15 Jun 2021 report, 47× the same report last year. Two unrelated kinds of activity within 133 days.
Short interest and volume: Short interest spike, became public on 25 Feb 2021
Short interest and volume: Short interest spike, became public on 10 Mar 2021
Attention: Wikipedia attention spike, became public on 23 Mar 2021
Short interest and volume: Short interest spike, became public on 25 Mar 2021
Short interest and volume: Short interest spike, became public on 13 Apr 2021
Short interest and volume: Short interest spike, became public on 27 Apr 2021
Short interest and volume: Short interest spike, became public on 12 May 2021
Short interest and volume: Short interest spike, became public on 26 May 2021
Short interest and volume: Short interest spike, became public on 10 Jun 2021
Short interest and volume: Short interest spike, became public on 26 Jun 2021
Short interest and volume: Short interest spike, became public on 13 Jul 2021
The week of 15 Mar 2021 against the 26 weeks before it.
this weekearliernormal: 34KSee the evidence (11 changes)
Short interest and volume: Short interest spike became public on 25 Feb 2021
AstraZeneca had 77.9M shares sold short in the 12 Feb 2021 report, 9.9× the same report last year.
This period
77.9M (the 12 Feb 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+31.6
Same report last year
7.8M
History used
1,141 days
the 12 Feb 2021 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Mar 2021
AstraZeneca had 86.3M shares sold short in the 26 Feb 2021 report, 9.6× the same report last year.
This period
86.3M (the 26 Feb 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+35.2
Same report last year
9.0M
History used
1,155 days
the 26 Feb 2021 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Attention: Wikipedia attention spike became public on 23 Mar 2021
AstraZeneca drew 222K Wikipedia page views in the week of 15 Mar 2021, 38× the same week last year.
This period
222K (the week of 15 Mar 2021)
Normal week (median of 26 earlier)
34K
Typical spread (median absolute deviation)
17K
How far from its usual level
+7.5
Same week last year
5,786
History used
810 days
the week of 15 Mar 202126 earlier weeksnormal: 34K
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Short interest and volume: Short interest spike became public on 25 Mar 2021
AstraZeneca had 94.9M shares sold short in the 15 Mar 2021 report, 13× the same report last year.
This period
94.9M (the 15 Mar 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+39.0
Same report last year
7.2M
History used
1,172 days
the 15 Mar 2021 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Apr 2021
AstraZeneca had 98.6M shares sold short in the 31 Mar 2021 report, 21× the same report last year.
This period
98.6M (the 31 Mar 2021 report)
Normal report (median of 24 earlier)
4.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+40.5
Same report last year
4.6M
History used
1,188 days
the 31 Mar 2021 report24 earlier reportsnormal: 4.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Apr 2021
AstraZeneca had 107.3M shares sold short in the 15 Apr 2021 report, 26× the same report last year.
This period
107.3M (the 15 Apr 2021 report)
Normal report (median of 24 earlier)
5.1M
Typical spread (median absolute deviation)
1.7M
How far from its usual level
+40.5
Same report last year
4.1M
History used
1,203 days
the 15 Apr 2021 report24 earlier reportsnormal: 5.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 May 2021
AstraZeneca had 118.1M shares sold short in the 30 Apr 2021 report, 33× the same report last year.
This period
118.1M (the 30 Apr 2021 report)
Normal report (median of 24 earlier)
5.6M
Typical spread (median absolute deviation)
2.3M
How far from its usual level
+33.6
Same report last year
3.6M
History used
1,218 days
the 30 Apr 2021 report24 earlier reportsnormal: 5.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 May 2021
AstraZeneca had 125.4M shares sold short in the 14 May 2021 report, 35× the same report last year.
This period
125.4M (the 14 May 2021 report)
Normal report (median of 24 earlier)
6.2M
Typical spread (median absolute deviation)
3.1M
How far from its usual level
+25.5
Same report last year
3.6M
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 6.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Jun 2021
AstraZeneca had 132.1M shares sold short in the 28 May 2021 report, 42× the same report last year.
This period
132.1M (the 28 May 2021 report)
Normal report (median of 24 earlier)
6.4M
Typical spread (median absolute deviation)
4.0M
How far from its usual level
+21.0
Same report last year
3.2M
History used
1,246 days
the 28 May 2021 report24 earlier reportsnormal: 6.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2021
AstraZeneca had 135.1M shares sold short in the 15 Jun 2021 report, 47× the same report last year.
This period
135.1M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
6.7M
Typical spread (median absolute deviation)
5.1M
How far from its usual level
+16.8
Same report last year
2.9M
History used
1,264 days
the 15 Jun 2021 report24 earlier reportsnormal: 6.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jul 2021
AstraZeneca had 136.9M shares sold short in the 30 Jun 2021 report, 71× the same report last year.
This period
136.9M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
20.2M
Typical spread (median absolute deviation)
18.6M
How far from its usual level
+4.2
Same report last year
1.9M
History used
1,279 days
the 30 Jun 2021 report24 earlier reportsnormal: 20.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
1 Dec 2020confirmed
Confirmed across sources Attention and Institutional holdings
AstraZeneca(AZN): saw 106 13F filers open a new position in the quarter ended 30 Sep 2020, 2.0× the same quarter last year, while it drew 87K Wikipedia page views in the week of 23 Nov 2020, 15× the same week last year. Two unrelated kinds of activity within 14 days.
Institutional holdings: Many funds opening a new position, became public on 16 Nov 2020
Attention: Wikipedia attention spike, became public on 1 Dec 2020
The quarter ended 30 Sep 2020 against the 8 quarters before it.
this quarterearliernormal: 53.5See the evidence (2 changes)
Institutional holdings: Many funds opening a new position became public on 16 Nov 2020
AstraZeneca saw 106 13F filers open a new position in the quarter ended 30 Sep 2020, 2.0× the same quarter last year.
This period
106 (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
53.5
Typical spread (median absolute deviation)
7.5
How far from its usual level
+4.7
Same quarter last year
54
History used
2,557 days
the quarter ended 30 Sep 20208 earlier quartersnormal: 53.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Attention: Wikipedia attention spike became public on 1 Dec 2020
AstraZeneca drew 87K Wikipedia page views in the week of 23 Nov 2020, 15× the same week last year.
This period
87K (the week of 23 Nov 2020)
Normal week (median of 26 earlier)
16K
Typical spread (median absolute deviation)
4,565
How far from its usual level
+10.5
Same week last year
5,731
History used
698 days
the week of 23 Nov 202026 earlier weeksnormal: 16K
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
5 May 2020confirmed
Confirmed across sources Attention and Lobbying
AstraZeneca(AZN): reported $1.7M of lobbying spend for the quarter ended 31 Mar 2020, 1.4× the same quarter last year, while it drew 33K Wikipedia page views in the week of 27 Apr 2020, 7.6× the same week last year. Two unrelated kinds of activity within 14 days.
Lobbying: Lobbying spend jump, became public on 20 Apr 2020
Attention: Wikipedia attention spike, became public on 5 May 2020
The quarter ended 31 Mar 2020 against the 8 quarters before it.
this quarterearliernormal: $770KSee the evidence (2 changes)
Lobbying: Lobbying spend jump became public on 20 Apr 2020
AstraZeneca reported $1.7M of lobbying spend for the quarter ended 31 Mar 2020, 1.4× the same quarter last year.
This period
$1.7M (the quarter ended 31 Mar 2020)
Normal quarter (median of 8 earlier)
$770K
Typical spread (median absolute deviation)
$175K
How far from its usual level
+3.5
Same quarter last year
$1.2M
History used
3,288 days
the quarter ended 31 Mar 20208 earlier quartersnormal: $770K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.
Attention: Wikipedia attention spike became public on 5 May 2020
AstraZeneca drew 33K Wikipedia page views in the week of 27 Apr 2020, 7.6× the same week last year.
This period
33K (the week of 27 Apr 2020)
Normal week (median of 26 earlier)
6,322
Typical spread (median absolute deviation)
802
How far from its usual level
+22.5
Same week last year
4,352
History used
488 days
the week of 27 Apr 202026 earlier weeksnormal: 6,322
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
drew 6,503 Wikipedia page views in the week of 3 Aug 2026, 1.2× the same week last year.
Same week last year: 5,403; its normal week is 3,675.
See the evidence
This period
6,503 (the week of 3 Aug 2026)
Normal week (median of 26 earlier)
3,675
Typical spread (median absolute deviation)
324
How far from its usual level
+5.9
Same week last year
5,403
History used
2,777 days
the week of 3 Aug 202626 earlier weeksnormal: 3,675
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
saw 253 13F filers open a new position in the quarter ended 31 Mar 2026, 2.2× the same quarter last year.
Same quarter last year: 116; its normal quarter is 104.
See the evidence
This period
253 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
104
Typical spread (median absolute deviation)
21.5
How far from its usual level
+4.7
Same quarter last year
116
History used
4,565 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 104
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
drew 9,799 Wikipedia page views in the week of 6 Oct 2025, 1.9× the same week last year.
Same week last year: 5,280; its normal week is 5,013.
See the evidence
This period
9,799 (the week of 6 Oct 2025)
Normal week (median of 26 earlier)
5,013
Typical spread (median absolute deviation)
536
How far from its usual level
+6.0
Same week last year
5,280
History used
2,476 days
the week of 6 Oct 202526 earlier weeksnormal: 5,013
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
drew 13K Wikipedia page views in the week of 12 May 2025, 1.7× the same week last year.
Same week last year: 7,651; its normal week is 5,028.
See the evidence
This period
13K (the week of 12 May 2025)
Normal week (median of 26 earlier)
5,028
Typical spread (median absolute deviation)
328
How far from its usual level
+15.2
Same week last year
7,651
History used
2,329 days
the week of 12 May 202526 earlier weeksnormal: 5,028
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
had 17.0M shares sold short in the 28 Feb 2025 report, 1.8× the same report last year.
Same report last year: 9.3M; its normal report is 8.0M.
See the evidence
This period
17.0M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
8.0M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+3.9
Same report last year
9.3M
History used
2,618 days
the 28 Feb 2025 report24 earlier reportsnormal: 8.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 15.5M shares sold short in the 14 Feb 2025 report, 1.7× the same report last year.
Same report last year: 8.9M; its normal report is 8.0M.
See the evidence
This period
15.5M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
8.0M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.5
Same report last year
8.9M
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 8.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.9M shares sold short in the 31 Jan 2025 report, 4.1× the same report last year.
Same report last year: 4.1M; its normal report is 7.8M.
See the evidence
This period
16.9M (the 31 Jan 2025 report)
Normal report (median of 24 earlier)
7.8M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+4.5
Same report last year
4.1M
History used
2,590 days
the 31 Jan 2025 report24 earlier reportsnormal: 7.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 15.1M shares sold short in the 15 Jan 2025 report, 2.6× the same report last year.
Same report last year: 5.8M; its normal report is 7.7M.
See the evidence
This period
15.1M (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
7.7M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.0
Same report last year
5.8M
History used
2,574 days
the 15 Jan 2025 report24 earlier reportsnormal: 7.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
drew 30K Wikipedia page views in the week of 29 Apr 2024, 5.9× the same week last year.
Same week last year: 5,088; its normal week is 5,736.
See the evidence
This period
30K (the week of 29 Apr 2024)
Normal week (median of 26 earlier)
5,736
Typical spread (median absolute deviation)
450
How far from its usual level
+36.1
Same week last year
5,088
History used
1,951 days
the week of 29 Apr 202426 earlier weeksnormal: 5,736
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
had 16.4M shares sold short in the 13 May 2022 report, 87% below the same report last year.
Same report last year: 125.4M; its normal report is 7.7M.
See the evidence
This period
16.4M (the 13 May 2022 report)
Normal report (median of 24 earlier)
7.7M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+4.3
Same report last year
125.4M
History used
1,596 days
the 13 May 2022 report24 earlier reportsnormal: 7.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 163 13F filers open a new position in the quarter ended 30 Sep 2021, 1.5× the same quarter last year.
Same quarter last year: 106; its normal quarter is 67.5.
See the evidence
This period
163 (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
67.5
Typical spread (median absolute deviation)
14
How far from its usual level
+4.6
Same quarter last year
106
History used
2,922 days
the quarter ended 30 Sep 20218 earlier quartersnormal: 67.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Showing the newest 40 of 150 entries; narrow the window or the kind of data to see older ones.
Not listed: 12 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000901832
Ticker
AZN
Domain
astrazeneca.com
Hq location
|CAMBRIDGE|CB2 0 (1 unverified)
Lobbying client
astrazeneca, farragut partners on behalf of astra zeneca
Name
AstraZeneca PLC, ZENECA GROUP PLC
Uei
CF9NBBEJ6BY5, G2FBBTMF9F24
Wikidata
Q731938
Wikipedia
AstraZeneca
DOL H-1B labor condition applications and PERM certifications53 data points10 Nov 2025 to 31 Aug 2026
Federal lobbying disclosures (LDA)73 records, 279 data points26 Mar 1999 to 30 Sep 2026
SEC Form 13F institutional holdings26 records, 481 data points30 Jun 2013 to 10 Nov 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)11 records8 Mar 2016 to 24 Feb 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)144 data points31 Dec 2014 to 31 Dec 2025
SEC Form 4 insider transactions2 records, 8 data points22 May 2026 to 11 Sep 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards17 records, 1812 data points1 Oct 2007 to 3 Nov 2023
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026